Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Overlapping Onset and Sequential Progression of Vasculopathy in Multiple Organs in Sickle Cell Disease
source: American Society of Hematology
year: 2016
authors: Shruti Chaturvedi, Djamila Ghafuri, Adetola A. Kassim, Michael DeBaun
summary/abstract:Background: Sickle cell disease (SCD) is associated with vasculopathy in multiple vital organs, which ultimately leads to complications such as stroke, proliferative retinopathy, chronic kidney disease and pulmonary hypertension. Existing studies focus on single organ specific vasculopathy without an emphasis on shared mechanisms and simultaneous progression of vasculopathy in multiple organs. We conducted this retrospective cohort study to determine the onset and progression, as well as sequence of involvement of vasculopathy in the central nervous system (CNS), eye, kidney and lungs of adults with SCD.
Methods: Our institutional practice is to perform annual magnetic resonance imaging with magnetic resonance angiography (MRI/MRA, for CNS vasculopathy and silent cerebral infarcts), echocardiography (for tricuspid regurgitant jet velocity > 2.5 m/sec, a surrogate of pulmonary hypertension), retinal examination, and measurement of urinary albumin:creatinine ratio, and serum creatinine in all adults with SCD. All patients were followed until death or last clinical encounter. Data were summarized as counts and proportions. Multivariable logistic regression was used to identify associations of number of organs affected with mortality.
Results: We identified 280 adults with SCD followed for a median period of 66 months (interquartile range [IQR] 15.7 to 112 months). Median age was 31.1 (IQR 25.4 to 39.7) years and 49.6% were female. Over half (51.8%) were on hydroxyurea therapy. The prevalence of vasculopathy in different organs was: CNS, 37.8%; retinopathy 26.1%, proteinuria, 20.7% (nephropathy 5.71%); and pulmonary hypertension, 15.36%. There was no evidence of vasculopathy in 103 (36.8%) individuals. Of the remaining 177 (63.2%) adults, vasculopathy was present in one, two, three and all four end organs in100, 55, 18, and 4 individuals respectively. Median age of onset was earliest for CNS vasculopathy [25.42 (IQR 19.31, 38.85)] years followed by retinopathy [28.41 (IQR 23.04, 35.79)] years, proteinuria [31.25 (IQR 25.6, 46.0)] years, and pulmonary hypertension [33.08 (IQR 23.83, 47.17)] years (Figure 1). Mortality rate was 1.69 per 100 patient-years. Patients with vasculopathy affecting 3 or 4 organs had a significantly higher mortality rate than those with 0-2 organs affected by vasculopathy [odds ratio 5.50 (95%CI 4.49-20.35), p=0.007], adjusted for phenotype, age, sex, hydroxyurea therapy, and smoking status.
Conclusion: Vasculopathy in SCD occurs in multiple organs simultaneously, with a predisposition to affect the CNS first. These data strongly support that multiple vasculopathy is common, and when present in at least three organs, is associated with earlier mortality.
organization: Vanderbilt University Medical Center, Nashvilleread more
Related Content
-
Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemiaChildren with sickle cell anemia (SCA) s...
-
Sickle cell disease and albuminuria: recent advances in our understanding of sickle cell nephropathyAlbuminuria is considered to be a releva...
-
Patient Perspective: The Journey of Pain in Sickle Cell Diseasehttps://www.youtube.com/watch?v=F4raFO0e...
-
Only 21% of Kids with ADHD and SCD Are Treated for Attention DeficitA study of children with sickle cell dis...
-
Sickle Cell Treatments can Destroy Germ Cells in Boys, Affecting Fertility in Adulthood, Study SuggestsSome treatments for sickle cell disease ...
-
Today’s Faces of Sickle Cell Disease: Tesha SamuelsTesha Samuels was diagnosed with SCD at ...
-
Today’s Faces of Sickle Cell Disease: Jennelle StephensonJennelle Stephenson was diagnosed with S...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.